research centers


Search results: Found 12

Listing 1 - 10 of 12 << page
of 2
>>
Sort by

Article
Therapeutic study of rosacea by Azithromycin and Metronidazole

Author: Naseer A. Al-harchan* MBChB, MSc, PhD د. نصير عبد الامير الحرجان
Journal: Journal of the Faculty of Medicine مجلة كلية الطب ISSN: 00419419 Year: 2009 Volume: 51 Issue: 4 Pages: 429-432
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Summery:Background: Rosacea is a chronic disease that requires long-term systemic and or local therapy, which carries risk for systemic complications and adverse reactions and high recurrence rate. Patient and methods: Two groups of rosacea patient with at least 8 inflammatory papules and pustules, moderate to severe facial erythema (22 patient treated with oral azithromycin versus 18 patient treated with oral metronidazole) were studied at single medical center (medical city of Baghdad: department of dermatology and venereology , both for 60 days, Subjects were evaluated monthly for up to three months to determine the relapse rate. Main outcome measures: Inflammatory papules and pustules were counted at each visit, relapse were determined by the appearance of a clinically significant increase in number of papules and pustules. Erythema were classified to three grades: - 0=Nil, 1=mild to moderate, 2=severe. Patient satisfaction also classified to three grades: 0=no satisfaction, 1=partial satisfaction, 2=full satisfaction.Results: Most of the patients respond to treatment measured by at least 70% reduction in the number of inflammatory lesions. (21 patient versus 14 patient) completed the study and compare by assessing:- erythema improvement and papule and pustule count reduction and percentage of occurrence of side effects and relapse, and subjective assessment of the degree of patients satisfaction with their treatment Erythema were reduced after two months of treatment:- (56.6% to 33.3% for azithromycin group versus 43.5% to 66.7% for metronidazole group).Mean papules count reduced from (36.9 to 10 for azithromycin group versus 25.8 to 11 for metronidazole group). Mean pustule count reduced from (2.95 to 0.33 for azithromycin group versus 2.92 to 0.5 for metronidazole group). The percentage of relapse was 16.7% versus 83.3% for azithromycin and metronidazole group respectively. Complete satisfactions were 70% versus 30% and side effect were 20% versus 80% for azithromycin and metronidazole group respectively. Conclusion: For the above results treatment of rosacea by azithromycin is more effective, safer thanmetronidazole, although the coast is little higher.Key Words: Azithromycin , Rosacea .

Keywords

Azithromycin --- Rosacea


Article
Azithomycin as an adjunctive to non-surgical treatment in comparison with doxycycline in chronic periodontitis patients: 2-months randomized clinical trial

Authors: Saif S.Saleim سيف سهام سليم --- Raghad F. Abbas رغد فاضل عباس --- Suzan Ali سوزان علي
Journal: Journal of baghdad college of dentistry مجلة كلية طب الاسنان بغداد ISSN: 16800087 Year: 2012 Volume: 24 Issue: 1 Pages: 72-75
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Background: Antibiotic therapy can be used in very specific periodontal treatment situations such as in refractorycases of periodontal disease which is found to be more prevalent in smokers. The aim of study was to asses theclinical effect of systemic use of Azithromycin and Doxycycline as adjunctive to non surgical scaling and rootplanning in patients with chronic periodontitis.Materials and methods: The study participants were 21 adult male, divided to three groups. 1n: GI treated by nonsurgical root planning with systemic intake of Azithromycin of 500 mg once daily for three days only. In GIIDoxycycline 100mg once daily was given for one week in addition to non surgical root planning while in the G III(control group) the patients were treated only by a routine scaling and root planning with out using any type of drug..The periodontal parameters used are the following:- Plaque index system(PLI) Gingival index (GI),Probing pocketdepth (PPD) and Bleeding on probing (BoP)Results: The study based on three periodontal parameters to asses the results of study, first of which is plaque indexand there was a significant low in all groups from the base line until the 4th visit while the bleeding on probing showeda highly significant difference between the groups whom take antibiotics as an adjunctive to a non surgicaltreatment and the group with out antibiotics. While for probing pocket depth the difference was only between thegroups whom take Azithromycin and control group this difference was start in the 2nd visit until the last visitConclusion: Although both treatment strategies seemed to be a successful therapy, the adjunctive use of 500 mgazithromycin systemically enhanced the clinical results

Keywords

Azithromycin --- Doxycycline


Article
Efficacy of Azithromycin in Comparison with Metronidazole in the Treatment of Chronic Periodontitis

Author: Jawna’a K Mammdoh
Journal: Al-Rafidain Dental Journal مجلة الرافدين لطب الأسنان ISSN: 18121217 Year: 2011 Volume: 11 Issue: 18 Pages: 323-330
Publisher: Mosul University جامعة الموصل

Loading...
Loading...
Abstract

Aims: The aim of this study was to evaluate the clinical effects of systemic azithromycin as an adjunct to scaling and root planning (SRP) and compared it with metronidazole in the treatment of chronic per-iodontitis. Materials and Methods: Forty four patients with clinical diagnosis of chronic periodontitis underwent scaling and root planing were divided into three groups. The first group (n = 20) patients received azithromycin 500 mg once daily for 3 days plus SRP. The second group (n= 11) received met-ronidazole 500 mg 3 times daily for 7 days plus SRP. The third control group (n= 13) patient received SRP plus placebo treatment once daily for 3 days. Clinical measurement including gingival index, bleeding on probing and probing pocket depth were performed at the base line visit and 40 days after taking the treatment. Results: The results obtained at 40 days from the base line showed better signifi-cant improvement in all clinical parameters (p≤ 0.05) in the treated groups, except for bleeding on probing in control group were no significant improvement was reported. Azithromycin plus SRP give the greatest improvement in mean gingival index and bleeding on probing (p< 0.05) when compared with the control group but no significant differences were observed between metronidazole treated group and the control group. Conclusions: The adjunctive use of azithromycin with SRP has potential to improve periodontal health over SRP only and could be an interesting alternative to metronidazole from patients with chronic periodontitis


Article
Molecular Study of Azithromycin-Resistant P. aeruginosa

Author: Dalal S. AL-Rubaye1, Wasan W. AL-Bassam1, Mohammed Ab. L. Hamod1, Ilham Ab. H. K. AL-Rubaye2
Journal: Iraqi Journal of Biotechnology المجلة العراقية للتقانات الحياتية ISSN: 18154794 Year: 2015 Volume: 14 Issue: 2 Pages: 71-79
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

The aim of the present study was to investigate the occurrence of azithromycin resistance among P. aeruginosa swabs isolates. Out of 60 pus, burn and wound swabs, 16 (26.6%) P. aeruginosa were isolated. The susceptibilities of the P. aeruginosa isolates to the macrolides azithromycin, chloramphenicol and aminoglycosides streptomycin, gentamicin and kanamycin were evaluated by disc diffusion experiments. The azithromycin was observed to be less resistance with high susceptibilities rate 13 (81.25) as compared to aminoglycosides and chloramphenicol. Partial 23S rDNA gene sequences of 12 isolates demonstrate new single base substitution in the resistant isolates in positions A1807G, C1808A, A1823G and A1819G which confer the azithromycin resistance with low frequency rate 0.9 for each one. As we recommend the azithromycin is the drug of choice in P. aeruginosa treatment, further study is needed to whole 23S rDNA gene in local isolates to identify mutations outside the partial selected region.


Article
Efficacy and Safety of Combined Isotretinoin and Azithromycin for Treatment of Severe Nodulocystic Acne
فعالية وامان عقاري الايزوتريتينوين والازثرومايسين الفموي كعلاج لمرض حب الشباب الشديد التكيسي عند المرضى العراقيين

Author: Samer A. Dhaher,Muhammed R. Luaibi سامر عبدالامير ظاهر
Journal: The Medical Journal of Basrah University المجلة الطبية لجامعة البصرة ISSN: 02530759 Year: 2016 Volume: 34 Issue: 2 Pages: 68-76
Publisher: Basrah University جامعة البصرة

Loading...
Loading...
Abstract

Background: A combination of azithromycin & isotretinoin has been used for treatment of Severe nodulocystic acne before, however, an optimal scheduled doses regimen of such combination remained to be elucidated.Objectives: To evaluate the effectiveness, safety and tolerability of using a new combination of fixed low doses of isotretinoin and azithromycin in an alternative days regimen in treatment of severe nodulocystic acne in Iraqi patients.Patients and Methods: A prospective open-labeled clinical study in which 54 young adult and adolescent patients with severe nodulocystic acne were recruited for the study at the Department of Dermatology in Basra General Hospital during from May-October 2015. The patients were received a combination of fixed dose of isotretinoin 20 mg thrice weekly and 500 mg azithromycin given orally thrice weekly on alternating days and one day off for 12 weeks. The participants was assessed before, during and after treatment. The calculation of percentage and scoring of reduction of acne lesions was also carried out.Results: There was a marked reduction in the inflammatory lesions at the first 4 weeks of the treatment, with a significant clearance of 38.4% of the papular lesions, 63.5% of pustular and 43% of the nodular lesions. At the end of the study, there was a significant reduction in the number of the inflammatory lesions, with the clearance of 76% of the papules, 96% of the pustules and 86% of the nodules. The most frequent adverse effects reported was dryness of face and lips.Conclusion: Fixed dose of azithromycin 500 mg combined with isotretinoin 20 mg on alternating day regimen proved to be effective, safe & well tolerated regimen for treatment of severe nodulocystic acne with high score of patient satisfaction.

الخلفية: بالرغم من فعالية عقاري الايزوتريتينوين الازثرومايسين كعلاج لمرض حب الشباب الشديد التكيسي الا ان تحديد الجرعة المناسبة لكلا العقارين بحاجة الى توضيح وتحديد اكثر.اهداف البحث: تقييم فعالية وامان عقاري الايزوتريتينوين والازثرومايسين بجرع ثابتة ومحددة كعلاج لمرض حب الشباب الشديد التكيسي عند المرضى العراقيين.طريقة اجراء البحث والمرضى: دراسة مستقبلية غير مقارنة شملت 54 مريضا مصابا بمرض حب الشباب الشديد التكيسي, اجريت الدراسة في مستشفى البصرة العام للفترة من مايس ولغاية تشرين الاول 2015. اعطي المرضى جرع ثابتة من الايزوتريتينوين 20 ملغم ثلاث مرات اسبوعيا بالتناوب مع الازثرومايسين 500 ملغم ثلاث مرات اسبوعيا. تم تقييم الاستجابة للعلاج شهريا بواسطة حساب نسبة اختزال اعداد الآفات الجلدية مع تسجيل اي اثار جانبية مصاحبة.النتائج: كان هناك اختزال واضح في اعداد ونسب الآفات الجلدية ابتداء" من نهاية الشهر الاول لبدء العلاج حيت انخفضت نسبة الحطاطات الى 38.4 % ونسبة البثور الى 63.5% والتكيسات بنسبة 43%. في نهاية الدراسة كان هناك انخفاض بنسبة 76% في الحطاطات, 96% بنسبة البثور و 86% بنسبة التكيسات. كان جفاف الجلد والشفتين هي الاثار الجانبية الاكثر تسجيلا.الاستنتاجات: ان عقاري الايزوتريتينوين بجرعة 20 ملغم ثلاث مرات اسبوعيا بالتناوب مع الازثرومايسين بجرعة 500ملغم ثلاث مرات اسبوعيا علاجا فعالا وامينا لمرض حب الشباب الشديد التكيسي

Keywords

Isotretinoin --- Azithromycin --- Acne


Article
Beneficial Effect of Isotretinoin Gel As AdjunctiveTreatment to Oral Azithromycin in the Management of Facial Acne Vulgaris.

Author: Sabeeh A. Al-Mashhadani
Journal: Iraqi Academic Scientific Journal المجلة العراقية للاختصاصات الطبية ISSN: 16088360 Year: 2009 Volume: 8 Issue: 1 Pages: 7-10
Publisher: The Iraqi Borad for Medical Specialization المجلس العراقي للاختصاصات الطبية

Loading...
Loading...
Abstract

ABSTRACT:BACKGROUND:Acne is a multifactorial disease with multiple pathogenic factors, hence combination therapies are needed. Combination therapies using agents with complementary mechanisms of action increasingly are recognized as an effective strategy for treating acne.OBJECTIVE:The rationale of utilizing topical retinoids with azithromycin in treating facial acne vulgaris will be highlighted, particularly in relation to improvement.METHODS:A randomized, clinical trial was carried out at the outpatient Department of Dermatology and Venereology, Baghdad Teaching Hospital between April 2007 and August 2008.A total of 48 patients with moderate to severe papulopustular acne vulgaris were allocated to two groups, azithromycin and azithromycin plus isotretinoin gel, both groups received Azithromycin for two months. Azithromycin 250 mg was prescribed every day for one month and every other day for the following month. Patients in second group were instructed to apply Isotretinoin gel 0.05% once daily over a 3 months treatment period. The clinical assessment was done by counting the number of inflammatory lesions in three occasions: baseline, two months and three months.RESULT:After two months, both groups showed a statistically significant difference from the baseline in reducing inflammatory lesions and improving acne. Adding topical isotretinoin gel produced a higher percentage of reduction in their lesional counts, but differences between the two groups were not statistically significant. After three months, regression in the percentage of reduction of the lesional count from 57.7% to 32.4% in the first group. While in the second group the reduction was maintain in 69.8%.CONCLUSION:Adding topical 0.05 per cent isotretinoin gel to oral azithromycin enhances and maintains the rate of improvement of facial acne vulgaris.


Article
Comparative study between oral azithromycin and erythromycin in male patients with severe papulopustular acne.

Author: Sarmad Nory Gany; M.B.Ch.B ; MSc. Pharmacology.
Journal: KUFA MEDICAL JOURNAL مجلة الكوفة الطبية ISSN: 1993517X Year: 2010 Volume: 13 Issue: 2 Pages: 39-44
Publisher: University of Kufa جامعة الكوفة

Loading...
Loading...
Abstract

AbstractBack ground: Acne vulgaris is a common disorders affecting79-95% of the adolescent population . Azithromycin is one of systemic antibiotic that has been recently prescribed for treatment of acne. This nitrogen- containing macrolide is a methyl derivative of erythromycin.Aim of work: To compare between the effect of oral azithromycin and erythromycin in male patients with severe papulo pustular acne treated with topical benzoyl peroxide and erythromycin drugs. Patients and methods: Fourty male patients were divided into two equal groups, the first were given oral azithromycin and the second were given erythromycin , both groups were treated with a topical erythromycin and benzoyl peroxide gel .The patients responses evaluated in each visit at the end of 4, 8 and 12 weeks of treatment . Results: Although there was more reduction in the mean acne global score showed in the group 1 when compared with the group 2 , this difference was not a statistically significant, P>0.05. This study also showed that 85% of patients who completed the treatment had a positive response in a group 1 in a comparison to 75% in a group 2.Conclusion: There was a better clinical improvement in patients treated with azithromycin , but not to a statistically significant level.

الخلاصة:حب الشباب من الأمراض الشائعة التي تصيب الشباب بنسبة 79-95% ويعتبرعقار لازيثرومايسين من العلاجات الحديثة المستعملة لهذا الغرض وهو مشتق من عقار لارثرومايسين و كلاهما من مجموعة الماكرولايد.تهدف الدراسة إلى المقارنة بين تأثير عقار لازيثرومايسين و عقار لارثرومايسين لدى المرضى الذكور المصابين بحب الشباب الشديد من النوع الحبيبي والمتقيح والمعالجون موضعيا بالبنزويل بيروكسايد والارثرومايسين.أنجزت الدراسة على أربعين مريضا تم تقسيمهم إلى مجموعتين متساويتين المجموعة الأولى أعطيت دواء الازيثرومايسين اما المجموعة الثانية فقد أعطيت دواء الارثرومايسين و كلتا المجموعتين عولجت موضعيا بالبنزويل بيروكسايد ولارثرومايسين (الجل) , تم تقيم استجابة المرضى خلال زيارتهم في نهاية الأسبوع الرابع, الثامن والثاني عشر من العلاج. أظهرت الدراسة و بالرغم من النقصان الكبير بمتوسط معدل الكلوبل لحب الشباب في المجموعة الأولى بالمقارنة مع المجموعة الثانية, لا يوجد أي فرق معنوي إحصائيا P> 0.05, وكما أظهرت النتائج أن 85% من المرضى في المجموعة الأولى الذين أكملوا العلاج كانت استجابتهم موجبه, بالمقارنة مع 75% في المجموعة الثانية.استنتجت الدراسة ان هناك تحسننا سريريا واضحا لدى المرضى الذين عولجوا بدواء الازيثرومايسين ولكن ليس إلى المستوى الإحصائي المعنوي


Article
Comparative study between oral azithromycin and erythromycin in male patients with severe papulopustular acne.

Author: Sarmad Nory Gany; M.B.Ch.B ; MSc. Pharmacology.
Journal: KUFA MEDICAL JOURNAL مجلة الكوفة الطبية ISSN: 1993517X Year: 2010 Volume: 13 Issue: 2 Pages: 39-44
Publisher: University of Kufa جامعة الكوفة

Loading...
Loading...
Abstract

AbstractBack ground: Acne vulgaris is a common disorders affecting79-95% of the adolescent population . Azithromycin is one of systemic antibiotic that has been recently prescribed for treatment of acne. This nitrogen- containing macrolide is a methyl derivative of erythromycin.Aim of work: To compare between the effect of oral azithromycin and erythromycin in male patients with severe papulo pustular acne treated with topical benzoyl peroxide and erythromycin drugs. Patients and methods: Fourty male patients were divided into two equal groups, the first were given oral azithromycin and the second were given erythromycin , both groups were treated with a topical erythromycin and benzoyl peroxide gel .The patients responses evaluated in each visit at the end of 4, 8 and 12 weeks of treatment . Results: Although there was more reduction in the mean acne global score showed in the group 1 when compared with the group 2 , this difference was not a statistically significant, P>0.05. This study also showed that 85% of patients who completed the treatment had a positive response in a group 1 in a comparison to 75% in a group 2.Conclusion: There was a better clinical improvement in patients treated with azithromycin , but not to a statistically significant level.

الخلاصة:حب الشباب من الأمراض الشائعة التي تصيب الشباب بنسبة 79-95% ويعتبرعقار لازيثرومايسين من العلاجات الحديثة المستعملة لهذا الغرض وهو مشتق من عقار لارثرومايسين و كلاهما من مجموعة الماكرولايد.تهدف الدراسة إلى المقارنة بين تأثير عقار لازيثرومايسين و عقار لارثرومايسين لدى المرضى الذكور المصابين بحب الشباب الشديد من النوع الحبيبي والمتقيح والمعالجون موضعيا بالبنزويل بيروكسايد والارثرومايسين.أنجزت الدراسة على أربعين مريضا تم تقسيمهم إلى مجموعتين متساويتين المجموعة الأولى أعطيت دواء الازيثرومايسين اما المجموعة الثانية فقد أعطيت دواء الارثرومايسين و كلتا المجموعتين عولجت موضعيا بالبنزويل بيروكسايد ولارثرومايسين (الجل) , تم تقيم استجابة المرضى خلال زيارتهم في نهاية الأسبوع الرابع, الثامن والثاني عشر من العلاج. أظهرت الدراسة و بالرغم من النقصان الكبير بمتوسط معدل الكلوبل لحب الشباب في المجموعة الأولى بالمقارنة مع المجموعة الثانية, لا يوجد أي فرق معنوي إحصائيا P> 0.05, وكما أظهرت النتائج أن 85% من المرضى في المجموعة الأولى الذين أكملوا العلاج كانت استجابتهم موجبه, بالمقارنة مع 75% في المجموعة الثانية.استنتجت الدراسة ان هناك تحسننا سريريا واضحا لدى المرضى الذين عولجوا بدواء الازيثرومايسين ولكن ليس إلى المستوى الإحصائي المعنوي


Article
The Effects of Some New Macrolides on Psychomotor Performance in Humans.
تأثير بعض أدوية المايكرولايد الحديثة على الأداء الحسي الحركي في الإنسان

Author: Waleed M. S. AL- Mashhadani د. وليد محمود صالح المشهداني
Journal: IRAQI JOURNALOF COMMUNITY MEDICINE المجلة العراقية لطب المجتمع ISSN: 16845382 Year: 2006 Volume: 19 Issue: 2 Pages: 172-177
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

Abstract:Objective. The study was designed to show the effects of single oral doses of new macrolides (Clarithromycin, Roxithromycin and Azithromycin) on psychomotor performance by using the computerized Leeds psychomotor Tester...Setting: Department of Pharmacology, College of Medicine, Al-Mustansiriya University, Baghdad- Iraq.Design: double-blind, balanced and controlled study.Main outcome measures: Choice reaction time (CRT), recognition reaction time (RRT) movement reaction time (MRT), and critical flicker fusion Frequency (CFF). These parameters were recorded before treatment and 2 hours interval taking 2 readings post treatmentResults: The results showed that the changes in the CRT,RRT ,MRT and CFF values following the three new macrolides treatments ,not significantly different between the four treated groups , nor across the two hours intervals of the study. Conclusion: Single oral doses of the new macrolides Clarithromycin (500 mg) Roxithromycin (150 mg) and Azithromycin (250 mg)have no impairment effects on the sensorimotor and arousal states in . These findings increase the safely profile of the new macrolides.Key wards: Macrolides, Psychomotor Performance, Clarithromycin, Azithromycin, Roxithromycin

الملخص:في بحث تميز بالتعابرية والتعمية المزدوجة تم دراسة تأثير جرع منفردة فموية لأدوية حديثة من مجموعة المايكرزلايد) كليريثروميسين ,روكسي ثروميسين , و أزي ثروميسين )على الأداء الحسي الحركــي في 32 شخص أصحاء متطوعين وشملت القياسات زمن الاختبار المعقد بجزأيه زمن التميز وزمن الحركة مع قياس التردد الحرج التذبذبي الاندماجي وأعطيت العلاجات عشوائيا حسب تصميم المربعين ألاتينيين 0 تم قياس مؤشرات الأداء الحسـي ـ الحركي قبل العلاج وبعده في الساعة الثانية والساعة الرابع باستخدام جهاز ليدز كومبيوتر لقياس الأداء الحسي الحركي اظهر تحليل النتائج إحصائيا ب ANOVA عدم وجود تغير إحصائي معتد في معدلات زمن الاختبار المعقد وزمني التميز والحركة و كذا في معدل التردد الحرج التذبذبي الاندماجي بعد العلاجات المذكورة مقارنة بالغفل وعلى مدى القراءات جميعا تم الاستنتاج بان الجرع الفموية المنفردة لهذه الأدوية الحديثة ليس لها تأثير مثبط على مؤشرات الأداء الحسي الحركي في الإنسان بعناصرها المختلفة وهذا يزيد من سلامة استعمالها وخاصة أثناء أداء الأعمال التي تتطلب أداء حسيا حركيا كاملا واستجابة صحيحة


Article
Effect of Azithromycin in Treatment of Cutaneous Leishmaniasis
تأثير ازثرومايسين في علاج عدوى لیشمانیا الجلدیة (حبة بغداد)

Author: Dindar Sharif Qurtas
Journal: The Medical Journal of Basrah University المجلة الطبية لجامعة البصرة ISSN: 02530759 Year: 2018 Volume: 36 Issue: 2 Pages: 97-102
Publisher: Basrah University جامعة البصرة

Loading...
Loading...
Abstract

Introduction: Leishmaniasis is a vector born protozoal infection. Cutaneous leishmaniasis outbreak occurred during 2014 in Erbil governorate, Kurdistan-Iraq. First choice of its treatment is pentavalent antimony. Other options of treatment are available. Azithromycin is used as trial to be effective but human studies are lacking. Patients and Methods: Prospective randomized open labeled interventional study conducted on 63 patients. The sample divided in to two groups. Group A received only intra-lesional sodium stibogluconate and the group B received combination therapy of intra-lesional sodium stibogluconate and azithromycin 500 mg orally. Follow up done for lesions’ healing at 6th week and at the end of 8th week of therapy.Results: Nodular lesions were dominant morphology among the Lesions (71.5%). Lesions mostly were ulcerated (59%). Mean duration of lesions were 3 ± 1.1 and 2.4 ± 1.8 weeks in patients of group A and B respectively. At 6th week in patients of group A, there were 13(41.9%) patients with complete healing of the lesions, while in group B it was found in 23(71.8%) patients. At the end of 8th week group A patients showed complete healing in 21(67.7%) patients while in patients of group B complete healing found in 27(84.3%). Conclusions: Results of this study concludes that combination therapy of azithromycin and intra-lesional sodium stibogluconate provides more therapeutic effect if compared with the effect of intra-lesional sodium stibogluconate alone.

المقدمة: عدوى اللشمانیا هو مرض طفيلي متوطن في الحشرات. شهدت مدينة اربيل –كردستان العراق انتشار وبائي لعدوى لیشمانیا الجلدیة (حبة بغداد) في عام 2014. العلاج الاساسي الاولي لهذه العدوى هو- بنتا فالنت انتيموني, خيارات اخرى لعلاج هذه العدوى ايضا متوفرة. المضاد الحيوي ازثرومايسين استخدم بحثيا كعلاج فعال لعدوى حبة بغداد الجلدية ولكن هذه البحوث تخلو من التجارب البشرية.خطة البحث: اجريت دراسة بحثية تداخلية مستقبلية عشوائية على 63 مريض. تم فرز العينة البحثية الى مجموعتين. المجموعة الاولى –استخدم في علاجها زرق ابر صوديم ستبوكلوكونيت بشكل مباشر داخل العدوى الجلدية فقط لا غير. المجموعة الثانية-استخدم في علاجها كل من زرق ابر صوديوم ستبوكلوكونيت المباشرة بالإضافة الى استخدام المضاد الحيوي ازثرومايسين كعلاج مرافق وبجرعه 500 ملغم حبوب فموية. تم متابعه المسار العلاجي للعدوى الجلدية خلال الاسبوع السادس وفي نهاية الاسبوع الثامن من العلاج.النتائــج:•تدمل في اغلب العدوات الجلدية بنسبة 71.5 % بينما تصل نسبة القروح في هذه العدوات الى59%.•المتوسط الوقتي للعلاج يتراوح من 3.3± 1.1 اسبوع , 2.4±1.8 اسبوع لكل من المجموعة الاولى والثانية على التوالي.•في الاسبوع السادس من المجموعة الاولى يصل عدد المرضى الذين تم شفائهم بشكل كامل من العدوى الجلدية الى 13 مريض (نسبة 41.9%),بينما يصل عدد شفاء المرضى في المجموعة الثانية الى 23 مريض (بنسبة 71.8%).•في نهاية الاسبوع الثامن وصل عدد المرضى الذين تم شفائهم بشكل كامل من العدوى الجلدية الى 21 مريض (بنسبة 67.7%),بينما وصلت نسبة الشفاء في المجموعة الثانية الى 84% ما يعادل 27 مريض.الاستنتاج: النتائج المستنبطة من هاذا البحث تدعم اقتران المضاد الحيوي ازثرومايسين مع ابر الصوديوم ستيبوكلوكونيت لتعطي فعالية علاجية اكثر مقارنتا مع ابر الصوديوم ستبوكلوكونيت لوحدها.

Listing 1 - 10 of 12 << page
of 2
>>
Sort by
Narrow your search

Resource type

article (12)


Language

English (10)

Arabic and English (2)


Year
From To Submit

2018 (1)

2016 (1)

2015 (1)

2013 (1)

2012 (2)

More...